Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for glaucoma, corneal disorders and retinal diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco. A live and archived webcast will be accessible through the Investors section of the Glaukos website.
Glaukos (NYSE: GKOS), un'azienda specializzata in tecnologia farmaceutica e medica oftalmica per glaucoma, disturbi corneali e malattie retiniche, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La presentazione è programmata per martedì 14 gennaio 2025, alle 17:15 PT a San Francisco. Sarà possibile accedere a una diretta e a un webcast registrato attraverso la sezione per investitori del sito web di Glaukos.
Glaukos (NYSE: GKOS), una empresa especializada en tecnología farmacéutica y médica oftálmica para glaucoma, trastornos corneales y enfermedades de la retina, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. La presentación está programada para el martes 14 de enero de 2025, a las 17:15 PT en San Francisco. Una transmisión en vivo y una grabación estarán disponibles a través de la sección de inversores del sitio web de Glaukos.
글라우코스 (NYSE: GKOS)는 녹내장, 각막 질환 및 망막 질환을 위한 안과 제약 및 의료 기술을 전문으로 하는 회사로, 제43회 JP모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 발표는 2025년 1월 14일 화요일 오후 5시 15분 PT에 샌프란시스코에서 예정되어 있습니다. 글라우코스 웹사이트 투자자 섹션을 통해 라이브 스트리밍과 아카이브된 웹캐스트를 이용할 수 있습니다.
Glaukos (NYSE: GKOS), une entreprise spécialisée dans les technologies pharmaceutiques et médicales ophtalmiques pour le glaucome, les troubles de la cornée et les maladies rétiniennes, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour le mardi 14 janvier 2025, à 17h15 PT à San Francisco. Une diffusion en direct et un webcast archivé seront accessibles via la section Investisseurs du site web de Glaukos.
Glaukos (NYSE: GKOS), ein Unternehmen, das sich auf ophthalmologische Pharma- und Medizintechnologie für Glaukom, Hornhautkrankheiten und Netzhauterkrankungen spezialisiert hat, gab seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt. Die Präsentation ist für Dienstag, den 14. Januar 2025, um 17:15 Uhr PT in San Francisco angesetzt. Eine Live-Übertragung und ein archivierter Webcast werden über den Investorenbereich der Glaukos-Website zugänglich sein.
- None.
- None.
A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217940197/en/
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
When is Glaukos (GKOS) presenting at the 2025 J.P. Morgan Healthcare Conference?
Where can investors watch Glaukos (GKOS) J.P. Morgan Healthcare Conference presentation?
What therapeutic areas does Glaukos (GKOS) focus on?
Which edition of the J.P. Morgan Healthcare Conference will GKOS attend in 2025?
